Literature DB >> 27134890

Metolazone Associated Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap.

Prabhat Kumar1, Ajay Chauhan2, Riyaz Charaniya3, Anindya Ghosh3, Vaibhav Tandon3.   

Abstract

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe mucocutaneous disease with high mortality rate. It is characterised by severe necrosis and detachment of the epidermis. Drugs are the most common triggering agent for SJS/TEN. These are commonly reported with the use of aromatic antiepileptics, antiretrovirals, allopurinol, NSAID'S and sulfonamide antibiotics. Non antibiotic sulfonamides rarely cause SJS/TEN. Metolazone is a well known diuretic and is extensively used by clinicians. Although this drug is in market for last several decades, no case of SJS/TEN has been reported till date. We report a rare case of metolazone induced SJS/TEN overlap in a 55-year-old lady.

Entities:  

Keywords:  Naranjo Probability Scale; SCORTEN score; Thiazide diuretic

Year:  2016        PMID: 27134890      PMCID: PMC4843276          DOI: 10.7860/JCDR/2016/17768.7404

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  13 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

2.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry.

Authors:  B Rzany; M Mockenhaupt; S Baur; W Schröder; U Stocker; J Mueller; N Holländer; R Bruppacher; E Schöpf
Journal:  J Clin Epidemiol       Date:  1996-07       Impact factor: 6.437

3.  Toxic epidermal necrolysis: five years of treatment experience from a burn unit.

Authors:  Bahar F Firoz; Jeffrey Scott Henning; Lee Ann Zarzabal; Brad H Pollock
Journal:  J Am Acad Dermatol       Date:  2012-01-27       Impact factor: 11.527

4.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.

Authors:  Jürgen Schneck; Jean-Paul Fagot; Peggy Sekula; Bruno Sassolas; Jean Claude Roujeau; Maja Mockenhaupt
Journal:  J Am Acad Dermatol       Date:  2007-10-04       Impact factor: 11.527

Review 5.  Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.

Authors:  Robert A Schwartz; Patrick H McDonough; Brian W Lee
Journal:  J Am Acad Dermatol       Date:  2013-08       Impact factor: 11.527

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Michael J Camilleri
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

8.  Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

Authors:  Amal Nassif; Armand Bensussan; Laurence Boumsell; Aurelien Deniaud; Homayoun Moslehi; Pierre Wolkenstein; Martine Bagot; Jean-Claude Roujeau
Journal:  J Allergy Clin Immunol       Date:  2004-11       Impact factor: 10.793

Review 9.  From erythema multiforme to toxic epidermal necrolysis. Same spectrum or different diseases?

Authors:  C Tomasini; F Derlino; P Quaglino; M Caproni; G Borroni
Journal:  G Ital Dermatol Venereol       Date:  2014-04       Impact factor: 2.011

Review 10.  Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Orphanet J Rare Dis       Date:  2010-12-16       Impact factor: 4.123

View more
  2 in total

1.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.

Authors:  Noel Frey; Michael Bodmer; Andreas Bircher; Susan S Jick; Christoph R Meier; Julia Spoendlin
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

2.  A Life-Threatening Case of Torsemide-Induced Toxic Epidermal Necrolysis Associated With the Treatment of Anasarca.

Authors:  Sujana Reddy; Bray K Aron; John Stewart
Journal:  Cureus       Date:  2022-03-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.